TMO Earnings Prediction
The chart below shows how TMO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TMO sees a -0.01% change in stock price 10 days leading up to the earnings, and a -1.87% change 10 days following the report. On the earnings day itself, the stock moves by -0.22%. This data can give you a slight idea of what to expect for the next quarter's release.
TMO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.39B
4.68%
7.52%
Gross Margin
42.32%
4.88%
3.62%
Operating Margin
19.65%
7.67%
10.33%
Net Margin
16.01%
8.54%
4.10%
EPS
4.78
13.81%
12.74%
No Data Available
TMO Earnings Analysis
Thermo Fisher Scientific Inc Corporation (TMO.N) Earnings Conference Call
Positive
Q4 Revenue Growth: Revenue in Q4 grew 5% year over year to $11.4 billion, reflecting strong operational execution.
Operating Income Increase: Adjusted operating income increased by 7% to $2.72 billion in Q4, with adjusted operating margins expanding by 50 basis points to 23.9%.
Q4 Adjusted EPS Increase: Adjusted EPS for Q4 rose 8% to $6.10 per share, demonstrating robust earnings performance.
Shareholder Returns 2024: In 2024, the company returned $4.6 billion to shareholders through stock buybacks and dividends, including $1 billion in Q4 alone.
Proteomics Research Enhancement: The acquisition of OlinQ was completed, enhancing capabilities in proteomics research, with the technology selected for a major human proteomic study.
Negative
Pharma Revenue Decline: Pharma and biotech revenue declined in the low single digits for the full year, primarily due to a mid single digit headwind from the runoff of vaccine and therapy related revenue.
Healthcare Revenue Decline: Diagnostics and healthcare revenue declined low single digits for the full year, significantly impacted by the runoff of COVID-19 testing related revenue.
North America Revenue Decline: North America experienced a low single digit decline in revenue for the full year, indicating a weakening market presence in a key region.
Specialty Diagnostics Margin Decline: The Specialty Diagnostics segment saw adjusted operating margin decrease by 30 basis points year over year, reflecting increased strategic investments despite revenue growth.
Flat Organic Revenue Growth: The Baruity Products and Biopharma Services segment reported flat organic revenue growth for the full year, hindered by the runoff of vaccines and therapies revenue.
TMO FAQs
How does TMO typically perform around its earnings report dates?
Is Thermo Fisher Scientific Inc (TMO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TMO Earning Call Sentiment
Earnings call transcript: Thermo Fisher Scientific beats Q4 2024 forecasts
TMO.N
-1.89%Positive
Despite strong Q4 financial performance and shareholder returns, the guidance reflects modest growth expectations and challenges such as supply chain issues and pandemic revenue runoff. The Q&A revealed uncertainties in China and unclear management responses on policy impacts, which may temper investor optimism. The raised EPS guidance and revenue growth are offset by flat full-year performance and economic uncertainties, leading to a neutral sentiment.
